Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Ritonavir oral tablet is a pharmacokinetic booster of multiple oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid (Nirmatrelvir 300 mg tablet + ritonavir 100 mg tablet co-administration package)
The first wave of shipments includes several countries, such as Germany, France and Austria
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
Key takeaways of Q3FY22 quarter & conference call highlights
Expected to open later this year, the facility will significantly increase distribution capacity to meet the growing demand for production materials by Ireland's biopharma industry
Proprietary implant-to-implant (i2i) device technology is used for communication between two implanted leadless pacemakers to regulate the heart rate
Results from the BiologyWorks k(now) molecular test were 99.1% in overall percent agreement with the results of the RT-PCR lab tests
Topline results from the randomized EMPATHY Part A study in acute Covid-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
Subscribe To Our Newsletter & Stay Updated
